Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Phathom Pharmaceuticals has appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary. Cook has a proven track record in pharmaceutical legal executive roles and brings expertise in corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy. She previously served as Senior Vice President, General Counsel at Sage Therapeutics.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, has appointed Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. The appointment was announced on June 23, 2025 [1].

Ms. Cook brings a wealth of experience in pharmaceutical legal executive roles, with a proven track record in corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy. She most recently served as Senior Vice President, General Counsel at Sage Therapeutics, Inc. [1].

"I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years," said Steven Basta, President and Chief Executive Officer of Phathom Pharmaceuticals. "Anne Marie will play a key role in shaping our corporate strategy." [1]

Ms. Cook is known for her expertise in leading legal activities across various aspects of the business, including commercialization, regulatory, compliance, intellectual property, and corporate governance. Prior to her role at Sage Therapeutics, she held leadership positions at Aegerion, ViaCell, and Biogen [1].

"I’m honored to join Phathom at such an exciting stage in its commercial evolution," said Anne Marie Cook. "Phathom has the potential to redefine the standard of care in acid-related GI diseases, and I’m energized by the opportunity to contribute to the company’s next chapter and to help create value for patients, physicians, and shareholders." [1]

Phathom Pharmaceuticals is focused on the development and commercialization of novel treatments for GI diseases. The company has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults [1].

The appointment of Ms. Cook underscores Phathom Pharmaceuticals' commitment to strengthening its legal and corporate governance framework, which is crucial for navigating the complex regulatory environment of the biopharmaceutical industry.

References:
[1] https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-appoints-anne-marie-cook-chief-legal
[2] https://www.globenewswire.com/news-release/2025/06/23/3103342/0/en/Phathom-Pharmaceuticals-Appoints-Anne-Marie-Cook-as-Chief-Legal-Officer-and-Corporate-Secretary.html